SlideShare ist ein Scribd-Unternehmen logo
1 von 39
Downloaden Sie, um offline zu lesen
Metabolic Syndrome
PRADEEP SINGH
M.Sc. Med. Biochemistry
HIMSR, Jamia Hamdard
Metabolic Syndrome or Syndrome - X
1. Introduction
2. Definition
3. Epidemiology
4. Pathophysiology
5. Treatment
1. Introduction
• The metabolic syndrome (MetS) is a major and escalating public-
health and clinical challenge worldwide in the wake of urbanization,
surplus energy intake, increasing obesity, and sedentary life habits.
• MetS confers a 5-fold increase in the risk of type 2 diabetes mellitus
(T2DM) and 2-fold the risk of developing cardiovascular disease (CVD)
over the next 5 to 10 years.
2. Definition
• MetS is defined by a constellation of an interconnected physiological,
biochemical, clinical, and metabolic factors that directly increases the
risk of atherosclerotic cardiovascular disease (ASCVD), T2DM, and all
cause mortality.
• Unhealthy body measurements and abnormal laboratory test results
include atherogenic dyslipidemia, hypertension, Impaired glucose
intolerance, proinflammatory state, and a prothrombotic state.
According to International Diabetes Federation, the metabolic
syndrome (2006) is defined as:
A) Central Obesity (Waist circumference)
and
B) Any two of the following:
1. Raised triglycerides: > 150 mg/dL
2. Reduced HDL Cholesterol: < 40 mg/dL in males, < 50 mg/dL in females.
3. Raised Blood Pressure: Systolic BP > 130 or diastolic BP > 85 mm Hg
4. Raised fasting plasma glucose: FBG > 100 mg/dL
• If BMI is > 30 kg/m2, central obesity can be assumed and waist
circumference doesn’t need to be measured.
Metabolic
Syndrome
High
Tryglycerides
Visceral
Obesity
Insulin
Resistance
Low HDL-
Cholesterol
Hypertension
3. Epidemiology
• Worldwide prevalence of MetS ranges from <10% to as much as 84%,
depending on the region, urban or rural environment, composition
(sex, age, race, and ethnicity) of the population studied, and the
definition of the syndrome used.
• In general, the IDF estimates that one-quarter of the world’s adult
population has the MetS.
• Higher socioeconomic status, sedentary lifestyle, and high body mass
index (BMI) were significantly associated with MetS.
• Differences in genetic background, diet, levels of physical activity,
smoking, family history of diabetes, and education all influence the
prevalence of the MetS and its components.
4. Pathophysiology
• MetS is a state of chronic low grade inflammation as a consequence
of complex interplay between genetic and environmental factors.
• Insulin resistance, visceral adiposity, atherogenic dyslipidemia,
endothelial dysfunction, genetic susceptibility, elevated blood
pressure, hypercoagulable state and chronic stress are the several
factors which constitute the syndrome.
4.1 Abdominal Obesity
• The “obesity epidemic” is principally driven by an
increased consumption of cheap, calorie dense food and
reduced physical activity.
• Adipose tissue respond rapidly and dynamically to
alterations in nutrient excess through adipocytes
hypertrophy and hyperplasia.
• With obesity and progressive adipocytes enlargement,
the blood supply to adipocytes may be reduced with
consequent hypoxia.
• Hypoxia has been proposed to be an inciting etiology of necrosis and
macrophage infiltration into adipose tissue that leads to an
overproduction of biologically active metabolites known as
adipocytokines.
• Adipocytokines includes free fatty acids (FFA), pro-inflammatory
mediators (TNF𝛼, IL-6, PAI-1, CRP).
• These adipocytokines results in a localized inflammation in adipose
tissue that propagates an overall systemic inflammation associated
with the development of obesity related comorbidities.
High Calorie
intake
Adipocytes
hypertrophy and
hyperplasia
Reduced blood
supply to
adipose tissue &
Hypoxia
Macrophage
infilteration,
Necrosis & Secretion
of adipocytokines
Localized
inflammation in
adipose tissue
Overall Systemic
Inflammation
4.1.1. FFA
• Splanchic FFA levels may contribute to the liver fat accumulation
commonly found in abdominal obesity.
• Acute exposure of skeletal muscle to the elevated level of FFA induces
insulin resistance by inhibiting the insulin-mediated glucose uptake.
• Chronic exposure of the pancreas to elevated FFA impairs a pancreatic
β-cell function.
• FFAs increase fibrinogen and PAI-1 production.
4.1.2 TNFα
• TNF-α acts as a paracrine mediator in adipocytes and appears to act
locally to reduce the insulin sensitivity.
• TNF-α induces adipocytes apoptosis and promotes insulin resistance
by the inhibition of the insulin receptor substrate 1 (IRS-1) signalling
pathway.
• TNF-α is positively associated with the body weight, waist
circumference and triglycerides (TGs), while negatively associated
with High density lipoprotein-cholesterol (HDL-C).
4.1.3 CRP
• High-sensitivity C-reactive protein (hs-CRP) has been developed and
used as a marker to predict CVD in metabolic syndrome and it was
recently used as a predictor for non-alcoholic fatty liver disease.
• CRP level is more likely to be elevated in obese insulin-resistant, but
not in obese insulin-sensitive subjects.
4.1.4 IL-6
• IL-6 is released by both adipose tissue and skeletal muscle in humans. It has
both an inflammatory and an anti-inflammatory action.
• IL-6 is also expressed in some parts of the brain such as hypothalamus, in
which it controls appetite and energy intake.
• IL-6 is a systemic adipokine, which not only impairs insulin sensitivity but is
also a major determinant of the hepatic production of CRP.
• IL-6 is positively associated with BMI, fasting insulin and the development
of T2DM and negatively associated with HDL-C.
4.1.5 PAI-1
• A serine protease inhibitor secreted from intra-abdominal adipocytes,
platelets and the vascular endothelium.
• It exerts its effect by inhibiting the tissue plasminogen activator (tPA)
and thus is considered as marker of fibrinolysis and atherothrombosis.
• It increases the risk of an intravascular thrombus and adverse
cardiovascular outcomes.
4.1.6 Adiponectin
• It inhibits hepatic gluconeogenic enzymes and the rate of an
endogenous glucose production in the liver.
• Adiponectin is inversely associated with CVD risk factors such as
blood pressure, LDL-C, TGs.
• Adiponectin expressions and secretions are reduced by TNF-α.
4.1.7 Leptin
• Leptin is an adipokinin involved in the regulation of satiety and energy
intake.
• Levels of leptin in the plasma increases during the development of
obesity and decreases during weight loss.
• Leptin receptors are located mostly in the hypothalamus and the
brainstem and signals through these receptors controls satiety,
energy expenditure and neuroendocrine function.
• Besides, its effect on appetite and metabolism, leptin also acts in the
hypothalamus to increase the blood pressure through activation of
sympathetic nervous system.
4.2 Insulin Resistance
• Insulin resistance is the main
pathology behind syndrome X.
• Insulin resistance individuals
demonstrate an impaired
glucose or tolerance by an
abnormal glucose challenge, an
elevated fasting glucose levels
and/or overt hyperglycemia.
How Insulin Acts (in normal condition)
Uptake of Glucose through GLUT-4 in adipose tissues and muscles (skeletal and
cardiac)
Insulin binding to tyrosine Kinase receptors
Release of insulin from β-cells of pancreas
Elevated blood glucose level
In Insulin Resistance states, insulin levels remain high and this promotes
hepatic lipogenesis.
β-cells reduce insulin output only if the blood glucose level falls, allowing
blood glucose to settle at a constant of approximately 5 mmol/L.
Insulin cannot bind to its receptors and thereby increases blood glucose
levels
If the cell phospholipid membrane is not “fluid” enough (i.e. it doesn’t
contain enough PUFA), insulin receptors are disrupted
How Insulin Acts (in abnormal condition)
Increase in serum lipid levels leads to atherosclerosis and
cardiovascular disease.
Glucagon also regulates FFA production through lipolysis
(Breakdown of stored lipids in the adipocytes)
Glucagon further increases blood sugar by converting liver
glycogen into glucose.
Without insulin, the muscle cells are unable to use glucose and
therefore release of glucagon from pancreas
Insulin Resistant States
• In an insulin-resistant person, normal levels of insulin do not have the
same effect in controlling blood glucose levels.
• During the compensated phase, insulin levels are higher and blood
glucose levels are still maintained.
• If the compensatory insulin secretion fails, then either fasting
(Impaired fasting glucose) or postprandial (Impaired glucose
tolerance) glucose concentration increases.
• Eventually, type 2 diabetes occur when glucose levels become higher
throughout the day as the resistance increases and compensatory
insulin secretion fails.
• The elevated insulin levels have additional effects that cause further
abnormal biological effects throughout the body.
Factors Influencing Insulin Resistance
Diet
• It is well known that insulin resistance commonly coexist with obesity.
• Saturated fat appears to be the most effective at producing insulin
resistance.
• High fat diet has the tendency to result in calorie intake that is far in
excess from our energy needs, resulting in rapid weight gain.
• IR is positively correlate with fat intake and negatively correlated with
dietary fibre intake.
PUFA
• In the long term, diet has the potential to change the ratio of
polyunsaturated to saturated phospholipids in cell membrane,
correspondingly changing cell membrane fluidity.
• It is hypothesized that increasing cell membrane fluidity by increasing
PUFA concentration might result in an enhanced number of insulin
receptors and reduced insulin resistance.
Advanced Glycated End Products
• AGE: Elevated blood glucose
levels leads to increased
glycation of proteins with
changes in protein function
throughout the body.
• These are called Advanced
Glycated End products and
contribute to the end organ
damages of T2DM.
4.3 Dyslipidemia
• Insulin normally suppresses lipolysis in adipocytes, so an impaired insulin
signalling increases lipolysis resulting in increased FFA levels. In the liver,
FFAs serve as a substrate for the synthesis of TGs.
• Insulin normally degrades apoB through PI3K-dpendent pathway, so an
insulin resistance directly increases VLDL production.
• Insulin regulates the activity of lipoprotein lipase, the rate limiting and
major mediator of VLDL clearance. VLDL is metabolized to remnant
lipoproteins and small dense LDL, both of which can promote atheroma
formation.
• The TGs in VLDL are transferred to HDL by cholesterol ester transfer
protein (CETP) in exchange for cholesteryl esters, resulting in TG-
enriched HDL and cholesteryl enriched VLDL particles.
• TG-enriched HDL is a better substrate for hepatic lipase so it is rapidly
cleared from the circulation, leaving a few HDL particles to participate
in a reverse cholesterol transport from the vasculature.
• It is believed that dyslipidemia associated with insulin resistance is a
direct consequence of increased VLDL secretion by the liver.
Atherosclerotic disease
Increased Oxidative stress and Endothelial dysfunction
Increased TGs enriched VLDL secretion by the liver
Increased FFAs level in the plasma
4.4 Hypertension
• Essential hypertension is frequently associated with obesity, glucose
intolerance and dyslipidemia.
• Both hyperglycemia and hyperinsulinemia activate the Renin Angiotensin
System (RAS) by increasing the expression of angiotensinogen, Angiotensin
II (AT II) and the AT 1 receptor, which in concert may contribute to the
development of hypertension in patients with insulin resistance.
• Insulin resistance and hyperinsulinemia leads to Sympathetic Nervous
System accumulation. As a result, the kidney increase sodium reabsorption,
the heart increases cardiac output and arteries respond with
vasoconstriction resulting in hypertension.
4.5 Genetic Factors
• Some people who are not obese by traditional measures nevertheless
are insulin-resistant and have abnormal levels of metabolic risk
factors.
• These includes:
─ Individuals with T2D parents
─ Being black, Hispanic (Related to spain), American Indian or Asian
• South Asian in Urban and migrant environments may be at a higher
risk of CHD due to the confluence of
1. Genetic factors that predispose to higher cholesterol levels and a possible
“thrifty gene” effect.
2. Environmental influences that lead to weight gain.
4.6 Chronic Stress and Glucocorticoid (GC) Action
• Chronic hypersecretion of stress mediators such as cortisol, may lead to the
visceral fat accumulation, low growth hormone secretion and
hypogonadism.
• GCs increase the activities of enzymes involved in fatty acid synthesis and
promote the secretion of lipoproteins; induce the hepatic gluconeogenic
pathway; promote the differentiation of preadipocytes to adipocytes,
which could lead to an increased body fat mass.
• GCs inhibit an insulin-stimulated uptake of amino acids by adipocytes and
increase lipolysis which leads to peripheral insulin resistance.
4.7 Sedentary lifestyle
• Sedentary lifestyle increases the likelihood of development of insulin
resistance.
Treatment
5. Treatment
5.1 Lifestyle Modification (Smoking etc.)
5.2 Weight Reduction (calorie restriction e.g., 500 Kcal/d deficit)
5.3 Diet (PUFA)
5.4 Physical Activity
5.5 Pharmacological Approach:
1. Appetite suppressants (Phentermine, Sibutramine ) and inhibitors of
nutrient absorption ( Orlistat)
2. Oral hypoglycaemics (Metformin & Glimepiride)
3. Antihypertensives (Metoprolol)
4. Statins (Atorvastatin)
5. Aspirin
5.6 Bariatric Surgery
Thank You !!!

Weitere ähnliche Inhalte

Was ist angesagt?

Obesity Pathology
Obesity PathologyObesity Pathology
Obesity PathologyPranav S
 
Complications of Diabetes Mellitus
Complications of Diabetes MellitusComplications of Diabetes Mellitus
Complications of Diabetes MellitusCarmela Domocmat
 
Diebetes mellitus type 1
Diebetes mellitus type 1Diebetes mellitus type 1
Diebetes mellitus type 1Priyank Ghanchi
 
Obesity - Pathophysiology, Etiology and management
Obesity - Pathophysiology, Etiology and management Obesity - Pathophysiology, Etiology and management
Obesity - Pathophysiology, Etiology and management Aneesh Bhandary
 
Secondary dyslipidemia
Secondary dyslipidemiaSecondary dyslipidemia
Secondary dyslipidemiaMarwa Khalifa
 
Obesity and its pathophysiology
Obesity and its pathophysiologyObesity and its pathophysiology
Obesity and its pathophysiologyAiswarya Thomas
 
Hypoglycemia
HypoglycemiaHypoglycemia
Hypoglycemiayuyuricci
 
Macrovascular disease in diabetes
Macrovascular disease in diabetesMacrovascular disease in diabetes
Macrovascular disease in diabetesPeninsulaEndocrine
 
Hepatic Encephalopathy -Pathophysiology,Evaluation And Management
Hepatic Encephalopathy -Pathophysiology,Evaluation And ManagementHepatic Encephalopathy -Pathophysiology,Evaluation And Management
Hepatic Encephalopathy -Pathophysiology,Evaluation And ManagementSantosh Narayankar
 
Obesity ,complication,metabolic syndrome by dr.Tasnim
Obesity ,complication,metabolic syndrome by dr.TasnimObesity ,complication,metabolic syndrome by dr.Tasnim
Obesity ,complication,metabolic syndrome by dr.Tasnimdr Tasnim
 

Was ist angesagt? (20)

Obesity
ObesityObesity
Obesity
 
Metabolic syndrome
Metabolic syndromeMetabolic syndrome
Metabolic syndrome
 
Obesity Pathology
Obesity PathologyObesity Pathology
Obesity Pathology
 
Obesity
ObesityObesity
Obesity
 
Complications of Diabetes Mellitus
Complications of Diabetes MellitusComplications of Diabetes Mellitus
Complications of Diabetes Mellitus
 
hypoglycemia
hypoglycemiahypoglycemia
hypoglycemia
 
Diebetes mellitus type 1
Diebetes mellitus type 1Diebetes mellitus type 1
Diebetes mellitus type 1
 
Obesity - Pathophysiology, Etiology and management
Obesity - Pathophysiology, Etiology and management Obesity - Pathophysiology, Etiology and management
Obesity - Pathophysiology, Etiology and management
 
diabetic nephropathy
diabetic nephropathydiabetic nephropathy
diabetic nephropathy
 
Type 1 diabetes mellitus
Type 1 diabetes mellitusType 1 diabetes mellitus
Type 1 diabetes mellitus
 
Secondary dyslipidemia
Secondary dyslipidemiaSecondary dyslipidemia
Secondary dyslipidemia
 
Dyslipidemia
DyslipidemiaDyslipidemia
Dyslipidemia
 
Obesity and its pathophysiology
Obesity and its pathophysiologyObesity and its pathophysiology
Obesity and its pathophysiology
 
Hypoglycemia
HypoglycemiaHypoglycemia
Hypoglycemia
 
Diabetic neuropathy
Diabetic neuropathyDiabetic neuropathy
Diabetic neuropathy
 
Macrovascular disease in diabetes
Macrovascular disease in diabetesMacrovascular disease in diabetes
Macrovascular disease in diabetes
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
Hepatic Encephalopathy -Pathophysiology,Evaluation And Management
Hepatic Encephalopathy -Pathophysiology,Evaluation And ManagementHepatic Encephalopathy -Pathophysiology,Evaluation And Management
Hepatic Encephalopathy -Pathophysiology,Evaluation And Management
 
Grave’s disease
Grave’s disease Grave’s disease
Grave’s disease
 
Obesity ,complication,metabolic syndrome by dr.Tasnim
Obesity ,complication,metabolic syndrome by dr.TasnimObesity ,complication,metabolic syndrome by dr.Tasnim
Obesity ,complication,metabolic syndrome by dr.Tasnim
 

Ähnlich wie Metabolic syndrome & its complications

METABOLIC SYNDROME.pptx
METABOLIC SYNDROME.pptxMETABOLIC SYNDROME.pptx
METABOLIC SYNDROME.pptxmbaeyigoddey
 
METABOLIC SYNDROME.pptx
METABOLIC SYNDROME.pptxMETABOLIC SYNDROME.pptx
METABOLIC SYNDROME.pptxMukundGurav
 
diabetes mallitus ppt.pptx
diabetes mallitus ppt.pptxdiabetes mallitus ppt.pptx
diabetes mallitus ppt.pptxSwati Yadav
 
#Diabetes mellitus disease ppt presentation
#Diabetes mellitus disease ppt presentation#Diabetes mellitus disease ppt presentation
#Diabetes mellitus disease ppt presentationrk17602629
 
Diabetes Mellitus MBC 120.pptx
Diabetes Mellitus MBC 120.pptxDiabetes Mellitus MBC 120.pptx
Diabetes Mellitus MBC 120.pptxchishimbalouis1
 
Approach to a patient of obesity
Approach to a patient of obesityApproach to a patient of obesity
Approach to a patient of obesityDrVeereshDhanni
 
Obesity And Its Hazards
Obesity And Its HazardsObesity And Its Hazards
Obesity And Its HazardsRanjit Saha
 
NAFLD non alcoholic fatty liver disease.pptx
NAFLD non alcoholic fatty liver disease.pptxNAFLD non alcoholic fatty liver disease.pptx
NAFLD non alcoholic fatty liver disease.pptxSyedFurqan30
 
metabolic syndrome by dr amber.pptx
metabolic syndrome by dr amber.pptxmetabolic syndrome by dr amber.pptx
metabolic syndrome by dr amber.pptxAmberMushtaq4
 
Firoz ahmad m.sc.bio chemistry ppt daibetic nephropathy copy
Firoz ahmad m.sc.bio chemistry ppt  daibetic nephropathy   copyFiroz ahmad m.sc.bio chemistry ppt  daibetic nephropathy   copy
Firoz ahmad m.sc.bio chemistry ppt daibetic nephropathy copyFirozAhmad30
 
Fuel homeostasis
Fuel homeostasisFuel homeostasis
Fuel homeostasistufpc1
 

Ähnlich wie Metabolic syndrome & its complications (20)

METABOLIC SYNDROME.pptx
METABOLIC SYNDROME.pptxMETABOLIC SYNDROME.pptx
METABOLIC SYNDROME.pptx
 
Metabolic Syndrome.pptx
Metabolic Syndrome.pptxMetabolic Syndrome.pptx
Metabolic Syndrome.pptx
 
Metabolic syndrome
Metabolic syndromeMetabolic syndrome
Metabolic syndrome
 
METABOLIC SYNDROME.pptx
METABOLIC SYNDROME.pptxMETABOLIC SYNDROME.pptx
METABOLIC SYNDROME.pptx
 
Obesity
ObesityObesity
Obesity
 
diabetes mallitus ppt.pptx
diabetes mallitus ppt.pptxdiabetes mallitus ppt.pptx
diabetes mallitus ppt.pptx
 
#Diabetes mellitus disease ppt presentation
#Diabetes mellitus disease ppt presentation#Diabetes mellitus disease ppt presentation
#Diabetes mellitus disease ppt presentation
 
Diabetes Mellitus MBC 120.pptx
Diabetes Mellitus MBC 120.pptxDiabetes Mellitus MBC 120.pptx
Diabetes Mellitus MBC 120.pptx
 
Approach to a patient of obesity
Approach to a patient of obesityApproach to a patient of obesity
Approach to a patient of obesity
 
Obesity And Its Hazards
Obesity And Its HazardsObesity And Its Hazards
Obesity And Its Hazards
 
NAFLD non alcoholic fatty liver disease.pptx
NAFLD non alcoholic fatty liver disease.pptxNAFLD non alcoholic fatty liver disease.pptx
NAFLD non alcoholic fatty liver disease.pptx
 
endocrine.pptx
endocrine.pptxendocrine.pptx
endocrine.pptx
 
obesity .ppt
obesity .pptobesity .ppt
obesity .ppt
 
2. diabetes mellitus
2. diabetes mellitus2. diabetes mellitus
2. diabetes mellitus
 
Metabolic syndrome
Metabolic syndromeMetabolic syndrome
Metabolic syndrome
 
diabetes mellitus
 diabetes mellitus diabetes mellitus
diabetes mellitus
 
metabolic syndrome by dr amber.pptx
metabolic syndrome by dr amber.pptxmetabolic syndrome by dr amber.pptx
metabolic syndrome by dr amber.pptx
 
Firoz ahmad m.sc.bio chemistry ppt daibetic nephropathy copy
Firoz ahmad m.sc.bio chemistry ppt  daibetic nephropathy   copyFiroz ahmad m.sc.bio chemistry ppt  daibetic nephropathy   copy
Firoz ahmad m.sc.bio chemistry ppt daibetic nephropathy copy
 
ADIPONECTIN.pptx
ADIPONECTIN.pptxADIPONECTIN.pptx
ADIPONECTIN.pptx
 
Fuel homeostasis
Fuel homeostasisFuel homeostasis
Fuel homeostasis
 

Mehr von Pradeep Singh Narwat

Comparative biology of rat and human
Comparative biology of rat and humanComparative biology of rat and human
Comparative biology of rat and humanPradeep Singh Narwat
 
Applications of Isotopes in Medicine
Applications of Isotopes in MedicineApplications of Isotopes in Medicine
Applications of Isotopes in MedicinePradeep Singh Narwat
 
Automation in Biochemistry (Autoanalyzers)
Automation in Biochemistry (Autoanalyzers)Automation in Biochemistry (Autoanalyzers)
Automation in Biochemistry (Autoanalyzers)Pradeep Singh Narwat
 
Major histocompatility complex (Antigen Presentation to T cells, Autoimmunity...
Major histocompatility complex (Antigen Presentation to T cells, Autoimmunity...Major histocompatility complex (Antigen Presentation to T cells, Autoimmunity...
Major histocompatility complex (Antigen Presentation to T cells, Autoimmunity...Pradeep Singh Narwat
 
Cell membrane (Plasma Membrane) & Cellular Junctions
Cell membrane (Plasma Membrane) & Cellular JunctionsCell membrane (Plasma Membrane) & Cellular Junctions
Cell membrane (Plasma Membrane) & Cellular JunctionsPradeep Singh Narwat
 
Junk DNA/ Non-coding DNA and its Importance (Regulatory RNAs, RNA interferen...
Junk DNA/ Non-coding DNA and its Importance  (Regulatory RNAs, RNA interferen...Junk DNA/ Non-coding DNA and its Importance  (Regulatory RNAs, RNA interferen...
Junk DNA/ Non-coding DNA and its Importance (Regulatory RNAs, RNA interferen...Pradeep Singh Narwat
 
Hemostatsis (Fibrinolysis - Plasminogen)
Hemostatsis (Fibrinolysis - Plasminogen)Hemostatsis (Fibrinolysis - Plasminogen)
Hemostatsis (Fibrinolysis - Plasminogen)Pradeep Singh Narwat
 
G protein coupled receptors (Type II Hormone Signaling)
G protein coupled receptors (Type II Hormone Signaling)G protein coupled receptors (Type II Hormone Signaling)
G protein coupled receptors (Type II Hormone Signaling)Pradeep Singh Narwat
 
Signal transduction processes connected to the changes in cytosolic calcium c...
Signal transduction processes connected to the changes in cytosolic calcium c...Signal transduction processes connected to the changes in cytosolic calcium c...
Signal transduction processes connected to the changes in cytosolic calcium c...Pradeep Singh Narwat
 
Purification of proteins (purification of enzymes)
Purification of proteins (purification of enzymes)Purification of proteins (purification of enzymes)
Purification of proteins (purification of enzymes)Pradeep Singh Narwat
 
Role of Nitric oxide & Nitric oxide synthases (NOS)
Role of Nitric oxide & Nitric oxide synthases (NOS)Role of Nitric oxide & Nitric oxide synthases (NOS)
Role of Nitric oxide & Nitric oxide synthases (NOS)Pradeep Singh Narwat
 
Determination of primary structure of proteins
Determination of primary structure of proteinsDetermination of primary structure of proteins
Determination of primary structure of proteinsPradeep Singh Narwat
 
Cytoskeleton & Extracellular matrix
Cytoskeleton & Extracellular matrixCytoskeleton & Extracellular matrix
Cytoskeleton & Extracellular matrixPradeep Singh Narwat
 

Mehr von Pradeep Singh Narwat (20)

Intellectual property rights
Intellectual property rightsIntellectual property rights
Intellectual property rights
 
Comparative biology of rat and human
Comparative biology of rat and humanComparative biology of rat and human
Comparative biology of rat and human
 
Applications of Isotopes in Medicine
Applications of Isotopes in MedicineApplications of Isotopes in Medicine
Applications of Isotopes in Medicine
 
Human gene therapy
Human gene therapyHuman gene therapy
Human gene therapy
 
Chromatography
ChromatographyChromatography
Chromatography
 
Automation in Biochemistry (Autoanalyzers)
Automation in Biochemistry (Autoanalyzers)Automation in Biochemistry (Autoanalyzers)
Automation in Biochemistry (Autoanalyzers)
 
Major histocompatility complex (Antigen Presentation to T cells, Autoimmunity...
Major histocompatility complex (Antigen Presentation to T cells, Autoimmunity...Major histocompatility complex (Antigen Presentation to T cells, Autoimmunity...
Major histocompatility complex (Antigen Presentation to T cells, Autoimmunity...
 
Cell membrane (Plasma Membrane) & Cellular Junctions
Cell membrane (Plasma Membrane) & Cellular JunctionsCell membrane (Plasma Membrane) & Cellular Junctions
Cell membrane (Plasma Membrane) & Cellular Junctions
 
Junk DNA/ Non-coding DNA and its Importance (Regulatory RNAs, RNA interferen...
Junk DNA/ Non-coding DNA and its Importance  (Regulatory RNAs, RNA interferen...Junk DNA/ Non-coding DNA and its Importance  (Regulatory RNAs, RNA interferen...
Junk DNA/ Non-coding DNA and its Importance (Regulatory RNAs, RNA interferen...
 
Hemostatsis (Fibrinolysis - Plasminogen)
Hemostatsis (Fibrinolysis - Plasminogen)Hemostatsis (Fibrinolysis - Plasminogen)
Hemostatsis (Fibrinolysis - Plasminogen)
 
G protein coupled receptors (Type II Hormone Signaling)
G protein coupled receptors (Type II Hormone Signaling)G protein coupled receptors (Type II Hormone Signaling)
G protein coupled receptors (Type II Hormone Signaling)
 
Signal transduction processes connected to the changes in cytosolic calcium c...
Signal transduction processes connected to the changes in cytosolic calcium c...Signal transduction processes connected to the changes in cytosolic calcium c...
Signal transduction processes connected to the changes in cytosolic calcium c...
 
Purification of proteins (purification of enzymes)
Purification of proteins (purification of enzymes)Purification of proteins (purification of enzymes)
Purification of proteins (purification of enzymes)
 
Role of Nitric oxide & Nitric oxide synthases (NOS)
Role of Nitric oxide & Nitric oxide synthases (NOS)Role of Nitric oxide & Nitric oxide synthases (NOS)
Role of Nitric oxide & Nitric oxide synthases (NOS)
 
Sodium - Potassium Pump
Sodium - Potassium Pump Sodium - Potassium Pump
Sodium - Potassium Pump
 
Transport across Plasma Membrane
Transport across Plasma Membrane Transport across Plasma Membrane
Transport across Plasma Membrane
 
Flow cytometry
Flow cytometryFlow cytometry
Flow cytometry
 
Electrophoresis
ElectrophoresisElectrophoresis
Electrophoresis
 
Determination of primary structure of proteins
Determination of primary structure of proteinsDetermination of primary structure of proteins
Determination of primary structure of proteins
 
Cytoskeleton & Extracellular matrix
Cytoskeleton & Extracellular matrixCytoskeleton & Extracellular matrix
Cytoskeleton & Extracellular matrix
 

Kürzlich hochgeladen

Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 

Kürzlich hochgeladen (20)

Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 

Metabolic syndrome & its complications

  • 1. Metabolic Syndrome PRADEEP SINGH M.Sc. Med. Biochemistry HIMSR, Jamia Hamdard
  • 2. Metabolic Syndrome or Syndrome - X 1. Introduction 2. Definition 3. Epidemiology 4. Pathophysiology 5. Treatment
  • 3. 1. Introduction • The metabolic syndrome (MetS) is a major and escalating public- health and clinical challenge worldwide in the wake of urbanization, surplus energy intake, increasing obesity, and sedentary life habits. • MetS confers a 5-fold increase in the risk of type 2 diabetes mellitus (T2DM) and 2-fold the risk of developing cardiovascular disease (CVD) over the next 5 to 10 years.
  • 4. 2. Definition • MetS is defined by a constellation of an interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of atherosclerotic cardiovascular disease (ASCVD), T2DM, and all cause mortality. • Unhealthy body measurements and abnormal laboratory test results include atherogenic dyslipidemia, hypertension, Impaired glucose intolerance, proinflammatory state, and a prothrombotic state.
  • 5. According to International Diabetes Federation, the metabolic syndrome (2006) is defined as: A) Central Obesity (Waist circumference) and B) Any two of the following: 1. Raised triglycerides: > 150 mg/dL 2. Reduced HDL Cholesterol: < 40 mg/dL in males, < 50 mg/dL in females. 3. Raised Blood Pressure: Systolic BP > 130 or diastolic BP > 85 mm Hg 4. Raised fasting plasma glucose: FBG > 100 mg/dL • If BMI is > 30 kg/m2, central obesity can be assumed and waist circumference doesn’t need to be measured.
  • 7. 3. Epidemiology • Worldwide prevalence of MetS ranges from <10% to as much as 84%, depending on the region, urban or rural environment, composition (sex, age, race, and ethnicity) of the population studied, and the definition of the syndrome used. • In general, the IDF estimates that one-quarter of the world’s adult population has the MetS.
  • 8. • Higher socioeconomic status, sedentary lifestyle, and high body mass index (BMI) were significantly associated with MetS. • Differences in genetic background, diet, levels of physical activity, smoking, family history of diabetes, and education all influence the prevalence of the MetS and its components.
  • 9. 4. Pathophysiology • MetS is a state of chronic low grade inflammation as a consequence of complex interplay between genetic and environmental factors. • Insulin resistance, visceral adiposity, atherogenic dyslipidemia, endothelial dysfunction, genetic susceptibility, elevated blood pressure, hypercoagulable state and chronic stress are the several factors which constitute the syndrome.
  • 10. 4.1 Abdominal Obesity • The “obesity epidemic” is principally driven by an increased consumption of cheap, calorie dense food and reduced physical activity. • Adipose tissue respond rapidly and dynamically to alterations in nutrient excess through adipocytes hypertrophy and hyperplasia. • With obesity and progressive adipocytes enlargement, the blood supply to adipocytes may be reduced with consequent hypoxia.
  • 11. • Hypoxia has been proposed to be an inciting etiology of necrosis and macrophage infiltration into adipose tissue that leads to an overproduction of biologically active metabolites known as adipocytokines. • Adipocytokines includes free fatty acids (FFA), pro-inflammatory mediators (TNF𝛼, IL-6, PAI-1, CRP). • These adipocytokines results in a localized inflammation in adipose tissue that propagates an overall systemic inflammation associated with the development of obesity related comorbidities.
  • 12. High Calorie intake Adipocytes hypertrophy and hyperplasia Reduced blood supply to adipose tissue & Hypoxia Macrophage infilteration, Necrosis & Secretion of adipocytokines Localized inflammation in adipose tissue Overall Systemic Inflammation
  • 13. 4.1.1. FFA • Splanchic FFA levels may contribute to the liver fat accumulation commonly found in abdominal obesity. • Acute exposure of skeletal muscle to the elevated level of FFA induces insulin resistance by inhibiting the insulin-mediated glucose uptake. • Chronic exposure of the pancreas to elevated FFA impairs a pancreatic β-cell function. • FFAs increase fibrinogen and PAI-1 production.
  • 14. 4.1.2 TNFα • TNF-α acts as a paracrine mediator in adipocytes and appears to act locally to reduce the insulin sensitivity. • TNF-α induces adipocytes apoptosis and promotes insulin resistance by the inhibition of the insulin receptor substrate 1 (IRS-1) signalling pathway. • TNF-α is positively associated with the body weight, waist circumference and triglycerides (TGs), while negatively associated with High density lipoprotein-cholesterol (HDL-C).
  • 15. 4.1.3 CRP • High-sensitivity C-reactive protein (hs-CRP) has been developed and used as a marker to predict CVD in metabolic syndrome and it was recently used as a predictor for non-alcoholic fatty liver disease. • CRP level is more likely to be elevated in obese insulin-resistant, but not in obese insulin-sensitive subjects.
  • 16. 4.1.4 IL-6 • IL-6 is released by both adipose tissue and skeletal muscle in humans. It has both an inflammatory and an anti-inflammatory action. • IL-6 is also expressed in some parts of the brain such as hypothalamus, in which it controls appetite and energy intake. • IL-6 is a systemic adipokine, which not only impairs insulin sensitivity but is also a major determinant of the hepatic production of CRP. • IL-6 is positively associated with BMI, fasting insulin and the development of T2DM and negatively associated with HDL-C.
  • 17. 4.1.5 PAI-1 • A serine protease inhibitor secreted from intra-abdominal adipocytes, platelets and the vascular endothelium. • It exerts its effect by inhibiting the tissue plasminogen activator (tPA) and thus is considered as marker of fibrinolysis and atherothrombosis. • It increases the risk of an intravascular thrombus and adverse cardiovascular outcomes.
  • 18. 4.1.6 Adiponectin • It inhibits hepatic gluconeogenic enzymes and the rate of an endogenous glucose production in the liver. • Adiponectin is inversely associated with CVD risk factors such as blood pressure, LDL-C, TGs. • Adiponectin expressions and secretions are reduced by TNF-α.
  • 19. 4.1.7 Leptin • Leptin is an adipokinin involved in the regulation of satiety and energy intake. • Levels of leptin in the plasma increases during the development of obesity and decreases during weight loss. • Leptin receptors are located mostly in the hypothalamus and the brainstem and signals through these receptors controls satiety, energy expenditure and neuroendocrine function. • Besides, its effect on appetite and metabolism, leptin also acts in the hypothalamus to increase the blood pressure through activation of sympathetic nervous system.
  • 20. 4.2 Insulin Resistance • Insulin resistance is the main pathology behind syndrome X. • Insulin resistance individuals demonstrate an impaired glucose or tolerance by an abnormal glucose challenge, an elevated fasting glucose levels and/or overt hyperglycemia.
  • 21. How Insulin Acts (in normal condition) Uptake of Glucose through GLUT-4 in adipose tissues and muscles (skeletal and cardiac) Insulin binding to tyrosine Kinase receptors Release of insulin from β-cells of pancreas Elevated blood glucose level
  • 22. In Insulin Resistance states, insulin levels remain high and this promotes hepatic lipogenesis. β-cells reduce insulin output only if the blood glucose level falls, allowing blood glucose to settle at a constant of approximately 5 mmol/L. Insulin cannot bind to its receptors and thereby increases blood glucose levels If the cell phospholipid membrane is not “fluid” enough (i.e. it doesn’t contain enough PUFA), insulin receptors are disrupted How Insulin Acts (in abnormal condition)
  • 23. Increase in serum lipid levels leads to atherosclerosis and cardiovascular disease. Glucagon also regulates FFA production through lipolysis (Breakdown of stored lipids in the adipocytes) Glucagon further increases blood sugar by converting liver glycogen into glucose. Without insulin, the muscle cells are unable to use glucose and therefore release of glucagon from pancreas
  • 24. Insulin Resistant States • In an insulin-resistant person, normal levels of insulin do not have the same effect in controlling blood glucose levels. • During the compensated phase, insulin levels are higher and blood glucose levels are still maintained. • If the compensatory insulin secretion fails, then either fasting (Impaired fasting glucose) or postprandial (Impaired glucose tolerance) glucose concentration increases.
  • 25. • Eventually, type 2 diabetes occur when glucose levels become higher throughout the day as the resistance increases and compensatory insulin secretion fails. • The elevated insulin levels have additional effects that cause further abnormal biological effects throughout the body.
  • 26. Factors Influencing Insulin Resistance Diet • It is well known that insulin resistance commonly coexist with obesity. • Saturated fat appears to be the most effective at producing insulin resistance. • High fat diet has the tendency to result in calorie intake that is far in excess from our energy needs, resulting in rapid weight gain. • IR is positively correlate with fat intake and negatively correlated with dietary fibre intake.
  • 27. PUFA • In the long term, diet has the potential to change the ratio of polyunsaturated to saturated phospholipids in cell membrane, correspondingly changing cell membrane fluidity. • It is hypothesized that increasing cell membrane fluidity by increasing PUFA concentration might result in an enhanced number of insulin receptors and reduced insulin resistance.
  • 28. Advanced Glycated End Products • AGE: Elevated blood glucose levels leads to increased glycation of proteins with changes in protein function throughout the body. • These are called Advanced Glycated End products and contribute to the end organ damages of T2DM.
  • 29. 4.3 Dyslipidemia • Insulin normally suppresses lipolysis in adipocytes, so an impaired insulin signalling increases lipolysis resulting in increased FFA levels. In the liver, FFAs serve as a substrate for the synthesis of TGs. • Insulin normally degrades apoB through PI3K-dpendent pathway, so an insulin resistance directly increases VLDL production. • Insulin regulates the activity of lipoprotein lipase, the rate limiting and major mediator of VLDL clearance. VLDL is metabolized to remnant lipoproteins and small dense LDL, both of which can promote atheroma formation.
  • 30. • The TGs in VLDL are transferred to HDL by cholesterol ester transfer protein (CETP) in exchange for cholesteryl esters, resulting in TG- enriched HDL and cholesteryl enriched VLDL particles. • TG-enriched HDL is a better substrate for hepatic lipase so it is rapidly cleared from the circulation, leaving a few HDL particles to participate in a reverse cholesterol transport from the vasculature. • It is believed that dyslipidemia associated with insulin resistance is a direct consequence of increased VLDL secretion by the liver.
  • 31. Atherosclerotic disease Increased Oxidative stress and Endothelial dysfunction Increased TGs enriched VLDL secretion by the liver Increased FFAs level in the plasma
  • 32. 4.4 Hypertension • Essential hypertension is frequently associated with obesity, glucose intolerance and dyslipidemia. • Both hyperglycemia and hyperinsulinemia activate the Renin Angiotensin System (RAS) by increasing the expression of angiotensinogen, Angiotensin II (AT II) and the AT 1 receptor, which in concert may contribute to the development of hypertension in patients with insulin resistance. • Insulin resistance and hyperinsulinemia leads to Sympathetic Nervous System accumulation. As a result, the kidney increase sodium reabsorption, the heart increases cardiac output and arteries respond with vasoconstriction resulting in hypertension.
  • 33. 4.5 Genetic Factors • Some people who are not obese by traditional measures nevertheless are insulin-resistant and have abnormal levels of metabolic risk factors. • These includes: ─ Individuals with T2D parents ─ Being black, Hispanic (Related to spain), American Indian or Asian • South Asian in Urban and migrant environments may be at a higher risk of CHD due to the confluence of 1. Genetic factors that predispose to higher cholesterol levels and a possible “thrifty gene” effect. 2. Environmental influences that lead to weight gain.
  • 34. 4.6 Chronic Stress and Glucocorticoid (GC) Action • Chronic hypersecretion of stress mediators such as cortisol, may lead to the visceral fat accumulation, low growth hormone secretion and hypogonadism. • GCs increase the activities of enzymes involved in fatty acid synthesis and promote the secretion of lipoproteins; induce the hepatic gluconeogenic pathway; promote the differentiation of preadipocytes to adipocytes, which could lead to an increased body fat mass. • GCs inhibit an insulin-stimulated uptake of amino acids by adipocytes and increase lipolysis which leads to peripheral insulin resistance.
  • 35. 4.7 Sedentary lifestyle • Sedentary lifestyle increases the likelihood of development of insulin resistance.
  • 37. 5. Treatment 5.1 Lifestyle Modification (Smoking etc.) 5.2 Weight Reduction (calorie restriction e.g., 500 Kcal/d deficit) 5.3 Diet (PUFA) 5.4 Physical Activity
  • 38. 5.5 Pharmacological Approach: 1. Appetite suppressants (Phentermine, Sibutramine ) and inhibitors of nutrient absorption ( Orlistat) 2. Oral hypoglycaemics (Metformin & Glimepiride) 3. Antihypertensives (Metoprolol) 4. Statins (Atorvastatin) 5. Aspirin 5.6 Bariatric Surgery

Hinweis der Redaktion

  1. Similar guidelines are given by WHO, European Group for the study of Insulin Resistance, NCEP ATP III, American Heart Association
  2. Now, we describe these factors.
  3. Pal – Plasminogen Activator Inhibitor
  4. Leptin-induced increase in renal sympathetic activity and blood pressure is mediated by the ventromedial and dorsomedial hypothalamus.
  5. GLUT-4 is sequestered in intracellular vesicles in muscle and fat cells.
  6. ChREBP (carbohydrate responsive element binding protein) has recently emerged as a major mediator of glucose action in the control of both glycolysis and lipogenesis in the liver. ChREBP upregulates the activity of AMPK which upregulates the activity of Acetyl-CoA Carboxylase which promotes lipogenesis in the liver.
  7. Among the AGE receptors the most studied is RAGE. RAGE receptors are physiologically mainly expressed on vascular, endothelial and smooth muscle cells and on monocyte/macrophage membranes.
  8. Orlistat is an inhibitor of gastric lipase